These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9020273)

  • 1. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.
    Fein AM; Bernard GR; Criner GJ; Fletcher EC; Good JT; Knaus WA; Levy H; Matuschak GM; Shanies HM; Taylor RW; Rodell TC
    JAMA; 1997 Feb; 277(6):482-7. PubMed ID: 9020273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
    Dhainaut JF; Tenaillon A; Le Tulzo Y; Schlemmer B; Solet JP; Wolff M; Holzapfel L; Zeni F; Dreyfuss D; Mira JP
    Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
    Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
    Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
    Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
    Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
    Abraham E; Naum C; Bandi V; Gervich D; Lowry SF; Wunderink R; Schein RM; Macias W; Skerjanec S; Dmitrienko A; Farid N; Forgue ST; Jiang F
    Crit Care Med; 2003 Mar; 31(3):718-28. PubMed ID: 12626975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group.
    Marmarou A; Nichols J; Burgess J; Newell D; Troha J; Burnham D; Pitts L
    J Neurotrauma; 1999 Jun; 16(6):431-44. PubMed ID: 10391361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.
    Angstwurm MW; Engelmann L; Zimmermann T; Lehmann C; Spes CH; Abel P; Strauss R; Meier-Hellmann A; Insel R; Radke J; Schüttler J; Gärtner R
    Crit Care Med; 2007 Jan; 35(1):118-26. PubMed ID: 17095947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
    Eisele B; Lamy M; Thijs LG; Keinecke HO; Schuster HP; Matthias FR; Fourrier F; Heinrichs H; Delvos U
    Intensive Care Med; 1998 Jul; 24(7):663-72. PubMed ID: 9722035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group.
    Poeze M; Froon AH; Ramsay G; Buurman WA; Greve JW
    Shock; 2000 Oct; 14(4):421-8. PubMed ID: 11049104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
    Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J;
    Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome--the ESSICS study.
    Werdan K; Pilz G; Müller-Werdan U; Maas Enriquez M; Schmitt DV; Mohr FW; Neeser G; Schöndube F; Schäfers HJ; Haverich A; Fraunberger P; Andersson J; Kreuzer E; Thijs LG;
    Crit Care Med; 2008 Mar; 36(3):716-23. PubMed ID: 18091548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
    Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
    Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
    Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
    Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
    Fisher CJ; Dhainaut JF; Opal SM; Pribble JP; Balk RA; Slotman GJ; Iberti TJ; Rackow EC; Shapiro MJ; Greenman RL
    JAMA; 1994 Jun; 271(23):1836-43. PubMed ID: 8196140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
    Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM
    Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group.
    Knaus WA; Harrell FE; LaBrecque JF; Wagner DP; Pribble JP; Draper EA; Fisher CJ; Soll L
    Crit Care Med; 1996 Jan; 24(1):46-56. PubMed ID: 8565538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
    Staubach KH; Schröder J; Stüber F; Gehrke K; Traumann E; Zabel P
    Arch Surg; 1998 Jan; 133(1):94-100. PubMed ID: 9438767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial.
    Giamarellos-Bourboulis EJ; Mylona V; Antonopoulou A; Tsangaris I; Koutelidakis I; Marioli A; Raftogiannis M; Kopterides P; Lymberopoulou K; Mouktaroudi M; Papageorgiou C; Papaziogas B; Georgopoulou AP; Tsaganos T; Papadomichelakis E; Gogos C; Ladas M; Savva A; Pelekanou A; Baziaka F; Koutoukas P; Kanni T; Spyridaki A; Maniatis N; Pelekanos N; Kotsaki A; Vaki I; Douzinas EE; Koratzanis G; Armaganidis A
    J Antimicrob Chemother; 2014 Apr; 69(4):1111-8. PubMed ID: 24292991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.